Acer Therapeutics Inc (NASDAQ:ACER) – Analysts at William Blair reduced their Q1 2018 earnings per share estimates for Acer Therapeutics in a report released on Thursday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter, down from their previous estimate of ($0.62). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Acer Therapeutics’ Q2 2018 earnings at ($0.83) EPS, Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.18) EPS, FY2018 earnings at ($3.72) EPS and FY2019 earnings at ($2.07) EPS.
Acer Therapeutics (NASDAQ:ACER) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.10).
Acer Therapeutics (ACER) opened at $19.46 on Monday. Acer Therapeutics has a 12 month low of $5.69 and a 12 month high of $22.63. The firm has a market capitalization of $141.01, a P/E ratio of -10.03 and a beta of 2.53.
Several institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC purchased a new stake in shares of Acer Therapeutics in the fourth quarter valued at approximately $2,091,000. J. Goldman & Co LP purchased a new stake in shares of Acer Therapeutics in the fourth quarter valued at approximately $1,496,000. Stonepine Capital Management LLC purchased a new stake in shares of Acer Therapeutics in the fourth quarter valued at approximately $1,385,000. Finally, Ardsley Advisory Partners purchased a new stake in shares of Acer Therapeutics in the fourth quarter valued at approximately $212,000. Hedge funds and other institutional investors own 7.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “William Blair Comments on Acer Therapeutics Inc’s Q1 2018 Earnings (ACER)” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3256446/william-blair-comments-on-acer-therapeutics-incs-q1-2018-earnings-acer.html.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.